Pharmaceuticals - Community Register

  

Community register of veterinary medicinal products


AUTHORISED  

Product information

Invented name: Proteq West Nile   
Auth. number : EU/2/11/129
Active substance : West Nile recombinant canarypox virus (vCP2017 virus)
ATC: Anatomical main group: QI - Immunologicals
Therapeutic subgroup: QI05 - Immunologicals for equidae
Pharmacological subgroup: QI05A - Horse
Chemical subgroup: QI05AX - Other immunologicals
Chemical substance: QI05AX - Other immunologicals
(See WHO ATCvet Index)
Indication: Active immunisation of horses from 5 months of age against West Nile disease by reducing the number of viraemic horses. If clinical signs are present, their duration and severity are reduced.
Marketing Authorisation Holder: Merial
29 avenue Tony Garnier, F-69007 Lyon, France
EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
10/08/2011 Centralised - Authorisation EMEA/V/C/2005 (2011)5834 of 05/08/2011
05/01/2012 Centralised - Variation EMEA/V/C/2005/IB/1
Updated with Decision(2012)4759 of 04/07/2012
06/07/2012 Centralised - Variation (2012)4759 of 04/07/2012
09/11/2012 Centralised - Variation EMEA/V/C/2005/IB/3
Updated with Decision(2014)479 of 24/01/2014
28/01/2014 Centralised - Yearly update (2014)479 of 24/01/2014